Intercept Pharmaceuticals - Business Information
Manufacturing · New Jersey, United States · 341 Employees
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New...
View Company Info for Free
Who is Intercept Pharmaceuticals
Top Competitors of Intercept Pharmaceuticals
Intercept Pharmaceuticals Org Chart
Intercept Pharmaceuticals Company Metrics
Total Funding Amount
Most Recent Funding Amount
Number of Funding Rounds
Top Companies in United States
Intercept Pharmaceuticals News & Media
- Wilmington, Delaware--(Newsfile Corp. - September 26, 2023) - Rigrodsky Law, P.A. is investigating Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ: ICPT) regarding possible breaches of fiduciary duties and other violations of law related to Intercept's agreement to be acquired by Alfasigma S.p.A. Under the terms of the agreement, Intercept shareholders will receive $19.00 per share in cash.To learn more about this investigation and your rights, visit:...
- The Italian pharma company is acquiring what was once one of the hottest stocks in the biotech sector, just months after the FDA rejected Intercept’s non-alcoholic steatohepatitis candidate.
ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to ShareholdersNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) to Alfasigma S.p.A. for $19.00 per share in cash is fair to Intercept shareholders. Halper Sadeh encourages Intercept shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or firstname.lastname@example.org or email@example.com. The investigation concerns wheth
- The FDA has again denied Intercept’s bid to have its obeticholic acid tablets approved in non-alcoholic steatohepatitis, forcing the company to abandon the indication and restructure operations.
Frequently Asked Questions regarding Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and ac...